
  
    
      
        Background_NNP
        Low_NNP intestinal_NN calcium_NN absorption_NN efficiency_NN in_IN humans_NNS
        is_VBZ common_JJ and_CC contributes_VBZ to_TO negative_JJ calcium_NN balance_NN and_CC
        bone_NN loss_NN [_NN 1_CD ]_NN ._. Recent_JJ epidemiological_JJ evidence_NN suggests_VBZ
        that_IN low_JJ fractional_JJ calcium_NN absorption_NN is_VBZ a_DT significant_JJ
        risk_NN factor_NN for_IN future_JJ osteoporotic_JJ hip_NN fracture_NN [_NN 2_CD ]_NN ._.
        The_DT primary_JJ homeostatic_JJ mechanism_NN for_IN altering_VBG calcium_NN
        absorption_NN in_IN response_NN to_TO low_JJ dietary_JJ calcium_NN intake_NN and_CC
        increased_VBN calcium_NN requirements_NNS during_IN growth_NN is_VBZ an_DT increase_NN
        in_IN plasma_NN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ,_, the_DT active_JJ hormonal_NN form_NN
        of_IN vitamin_NN D_NNP produced_VBD in_IN the_DT kidney_NN [_NN 3_CD ]_NN ._.
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP is_VBZ a_DT seco-steroid_JJ that_IN acts_NNS on_IN gene_NN
        transcription_NN through_IN a_DT nuclear_JJ steroid_NN receptor_NN protein_NN
        and_CC also_RB may_MD have_VB nongenomic_JJ actions_NNS mediated_JJ by_IN a_DT putative_JJ
        plasma_NN membrane_NN vitamin_NN D_NNP receptor_NN [_NN 4_CD ]_NN ._. Changes_NNS in_IN
        vitamin_NN D_NNP status_NN primarily_RB alter_VB the_DT rate_NN of_IN Ca_MD absorption_NN
        in_IN the_DT proximal_NN small_JJ intestine_NN ._. During_IN transcellular_NN
        calcium_NN transport_NN across_IN the_DT absorptive_JJ enterocyte_NN ,_, calcium_NN
        must_MD pass_VB across_IN an_DT apical_JJ brush_NN border_NN membrane_NN ,_, then_RB
        transverse_NN the_DT interior_NN of_IN the_DT cell_NN ,_, and_CC exit_NN against_IN an_DT
        electrochemical_JJ gradient_NN across_IN the_DT basolateral_NN membrane_NN ._.
        Changes_NNS in_IN the_DT rate_NN of_IN vectorial_NN Ca_MD transport_VB in_IN the_DT
        intestine_NN however_RB must_MD be_VB accomplished_VBN without_IN a_DT major_JJ
        disruption_NN in_IN the_DT free_JJ intracellular_NN Ca_NNP concentration_NN ,_,
        which_WDT is_VBZ used_VBN as_IN an_DT important_JJ intracellular_NN signal_NN in_IN the_DT
        enterocyte_NN [_NN 5_CD ]_NN as_IN in_IN other_JJ cells_NNS ._.
        It_PRP has_VBZ been_VBN known_VBN for_IN over_IN 30_CD years_NNS that_WDT vitamin_NN D_NNP
        status_NN influences_VBZ the_DT level_NN of_IN calbindin_NN D_NNP ,_, a_DT cytosolic_JJ
        calcium-binding_JJ protein_NN [_NN 6_CD ]_NN believed_VBN to_TO be_VB the_DT
        rate-limiting_JJ step_NN in_IN calcium_NN absorption_NN [_NN 7_CD ]_NN by_IN acting_VBG as_IN
        an_DT intracellular_NN calcium_NN ferry_NN or_CC chaperone_NN ._. Calcium_NNP
        extrusion_NN at_IN the_DT basolateral_NN membrane_NN is_VBZ an_DT active_JJ process_NN
        involving_VBG a_DT Ca-_NNP ATPase_NNP that_WDT may_MD also_RB be_VB affected_VBN by_IN vitamin_NN
        D_NNP status_NN [_NN 8_CD ]_NN ._. However_RB ,_, although_IN it_PRP has_VBZ been_VBN known_VBN for_IN
        more_JJR than_IN 20_CD years_NNS that_IN the_DT rate_NN of_IN Ca_MD transport_VB across_IN the_DT
        intestinal_NN brush_NN border_NN membrane_NN can_MD be_VB increased_VBN by_IN
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP [_NN 9_CD ]_NN ,_, the_DT identity_NN of_IN the_DT calcium_NN
        transport_NN protein_NN involved_VBN in_IN Ca_MD influx_NN has_VBZ not_RB been_VBN
        ascertained_JJ ._. Recently_RB ,_, two_CD novel_NN ,_, closely_RB related_VBN ,_,
        epithelial_NN calcium_NN channels_NNS ,_, CaT_NNP 1_CD (_( also_RB known_VBN as_IN ECaC_NNP 2_LS )_) and_CC
        ECaC_NNP 1_CD (_( also_RB known_VBN as_IN CaT_NNP 2_LS )_) ,_, have_VBP been_VBN cloned_VBN from_IN rat_NN [_NN 10_CD
        ]_NN and_CC rabbit_NN [_NN 11_CD ]_NN respectively_RB and_CC shown_VBN to_TO mediate_VB
        calcium_NN influx_NN when_WRB expressed_VBD in_IN 
        Xenopus_NNP oocytes_NNS ._. CaT_NNP 1_CD and_CC ECaC_NNP 1_CD are_VBP
        found_VBN in_IN several_JJ tissues_NNS ,_, including_VBG 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN
        D-_NNP responsive_JJ epithelia_NN in_IN the_DT intestine_NN and_CC kidney_NN ._. These_DT
        epithelial_NN calcium_NN channel_NN genes_NNS are_VBP products_NNS of_IN
        evolutionary_JJ local_JJ gene_NN duplication_NN found_VBD on_IN chromosome_NN 7_CD
        and_CC represent_VB a_DT new_JJ family_NN of_IN Ca-selective_NNP ion_NN channels_NNS
        involved_VBN in_IN active_JJ Ca_MD (_( re_NN )_) absorption_NN [_NN 12_CD ]_NN ._. Furthermore_RB ,_,
        it_PRP has_VBZ been_VBN suggested_VBN that_IN the_DT control_NN of_IN the_DT number_NN of_IN
        active_JJ channels_NNS at_IN the_DT cell_NN surface_NN is_VBZ critical_JJ for_IN
        regulation_NN of_IN active_JJ calcium_NN transport_NN and_CC that_IN the_DT
        epithelial_NN calcium_NN channel_NN could_MD confer_VB the_DT rate-limiting_JJ
        step_NN in_IN transcellular_NN calcium_NN transport_NN [_NN 13_CD ]_NN ._.
        Peptide_NNP hormones_NNS and_CC other_JJ cell_NN surface-acting_JJ signal_NN
        molecules_NNS trigger_VBP increases_NNS in_IN the_DT concentration_NN of_IN calcium_NN
        ions_NNS inside_IN the_DT cell_NN by_IN release_NN of_IN calcium_NN from_IN stores_NNS
        within_IN the_DT cell_NN ,_, or_CC activation_NN of_IN Ca_MD +_NN +_NN ion_NN channels_NNS in_IN the_DT
        plasma_NN membrane_NN allowing_VBG calcium_NN to_TO enter_VB from_IN outside_IN the_DT
        cell_NN ._. One_CD of_IN the_DT most_RBS common_JJ mechanisms_NNS that_WDT regulate_VB entry_NN
        of_IN calcium_NN is_VBZ by_IN capacitative_JJ or_CC store-operated_JJ calcium_NN
        entry_NN [_NN 14_CD ]_NN ._. The_DT epithelial_NN Ca-release_NNP activated_VBN channel_NN ,_,
        I_PRP 
        CRAC_NNP ,_, is_VBZ a_DT highly_RB calcium-selective_JJ
        plasma_NN membrane_NN ion_NN channel_NN that_WDT is_VBZ activated_VBN on_IN lowering_VBG
        of_IN either_DT intracellular_NN calcium_NN concentration_NN or_CC
        intracellular_NN calcium_NN stores_NNS ._. The_DT CaT_NNP 1_CD channel_NN has_VBZ been_VBN
        recently_RB expressed_VBN in_IN mammalian_JJ CHO_NNP cells_NNS and_CC patch_NN clamp_NN
        studies_NNS have_VBP shown_VBN it_PRP to_TO have_VB the_DT characteristics_NNS of_IN I_PRP 
        CRAC_NNP [_NN 15_CD ]_NN ._. Nearly_RB ubiquitous_JJ ,_,
        store-operated_JJ calcium_NN entry_NN is_VBZ essential_JJ in_IN a_DT wide_JJ variety_NN
        of_IN cellular_JJ processes_VBZ including_VBG muscle_NN contraction_NN ,_, protein_NN
        secretion_NN ,_, metabolism_NN ,_, cell_NN differentiation_NN ,_, cell_NN division_NN
        and_CC apoptosis_NNS [_NN 14_CD ]_NN ._.
        Intestinal_NNP calcium_NN absorption_NN is_VBZ increased_VBN after_IN feeding_VBG
        a_DT low_JJ calcium_NN diet_NN or_CC under_IN conditions_NNS of_IN increased_VBN calcium_NN
        needs_VBZ ,_, such_JJ as_IN during_IN growth_NN ,_, via_IN a_DT parathyroid_NN hormone_NN
        (_( PTH_NNP )_) -_: vitamin_NN D_NNP mediated_JJ process_NN [_NN 3_CD ]_NN ._. A_DT lowering_VBG of_IN
        serum_NN calcium_NN levels_NNS stimulates_NNS the_DT secretion_NN of_IN PTH_NNP that_IN
        then_JJ activates_NNS the_DT renal_JJ conversion_NN of_IN inactive_JJ
        25_CD -_: hydroxyvitamin_NN D_NNP to_TO the_DT active_JJ hormonal_NN metabolite_NN
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ._. At_IN the_DT intestine_NN ,_,
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ,_, acting_VBG through_IN a_DT nuclear_JJ receptor_NN ,_,
        stimulates_NNS transcription_NN of_IN vitamin_NN D-_NNP mediated_JJ genes_NNS ,_,
        including_VBG calbindin_NN D_NNP ,_, involved_VBN in_IN calcium_NN transport_NN
        thereby_RB acting_VBG as_IN the_DT primary_JJ hormonal_NN regulator_NN of_IN active_JJ
        intestinal_NN calcium_NN transport_NN [_NN 3_CD ]_NN ._. It_PRP is_VBZ thus_RB likely_JJ that_IN
        any_DT putative_JJ key_JJ molecular_JJ player_NN in_IN calcium_NN absorption_NN ,_,
        such_JJ as_IN CaT_NNP 1_CD or_CC ECaC_NNP 1_CD ,_, should_MD be_VB a_DT prime_JJ target_NN for_IN
        hormonal_NN regulation_NN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ._. However_RB ,_, to_TO
        date_NN ,_, neither_DT CaT_NNP 1_CD nor_CC ECaC_NNP 1_CD expression_NN has_VBZ been_VBN shown_VBN to_TO
        be_VB related_VBN to_TO serum_NN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP or_CC vitamin_NN D_NNP
        status_NN [_NN 10_CD 16_CD ]_NN ._.
        We_PRP have_VBP developed_VBN [_NN 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD ]_NN a_DT unique_JJ human_JJ
        intestinal_NN cell_NN culture_NN model_NN of_IN vitamin_NN D-_NNP mediated_JJ
        transepithelial_NN Ca_MD transport_VB using_VBG Caco-_NNP 2_CD cells_NNS ,_, a_DT colon_NN
        adenocarcinoma_NN cell_NN line_NN ._. This_DT cell_NN line_NN spontaneously_RB
        differentiates_NNS in_IN culture_NN and_CC expresses_VBZ biochemical_JJ and_CC
        morphological_JJ characteristics_NNS of_IN well-differentiated_JJ small_JJ
        intestine-like_JJ enterocytes_NNS [_NN 17_CD 23_CD ]_NN ._. We_PRP have_VBP previously_RB
        shown_VBN that_IN Caco-_NNP 2_CD cells_NNS possess_VBP a_DT classical_JJ nuclear_JJ vitamin_NN
        D_NNP receptor_NN [_NN 18_CD ]_NN that_IN directly_RB mediates_NNS vitamin_NN
        D-_NNP dependent_JJ gene_NN expression_NN [_NN 22_CD ]_NN ,_, and_CC exhibits_VBZ a_DT high_JJ
        degree_NN of_IN specificity_NN for_IN various_JJ vitamin_NN D_NNP metabolites_NNS and_CC
        analogs_NNS [_NN 20_CD 21_CD ]_NN ._. Most_JJS importantly_RB ,_, in_IN response_NN to_TO
        short-term_JJ (_( <_NN 24_CD h_NN )_) 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN ,_,
        Caco-_NNP 2_CD cells_NNS increase_VBP transepithelial_NN calcium_NN transport_NN [_NN
        17_CD ]_NN and_CC calbindin_NN D_NNP 
        9_CD K_NNP expression_NN [_NN 19_CD ]_NN ,_, a_DT cytosolic_JJ
        calcium_NN binding_JJ protein_NN ._. Kinetic_NNP analysis_NN of_IN Ca_MD transport_VB
        across_IN Caco-_NNP 2_CD monolayers_NNS grown_VBN on_IN permeable_JJ filter_NN supports_VBZ
        indicated_VBN that_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN increased_VBD
        the_DT V_NNP 
        max_NN of_IN Ca_MD transport_VB [_NN 17_CD ]_NN ,_, which_WDT would_MD
        be_VB consistent_JJ with_IN a_DT vitamin_NN D-_NNP dependent_JJ increase_NN in_IN the_DT
        number_NN of_IN calcium_NN transporters_NNS ._.
        In_IN the_DT current_JJ paper_NN ,_, we_PRP have_VBP used_VBN the_DT Caco-_NNP 2_CD cell_NN
        culture_NN model_NN to_TO demonstrate_VB that_IN CaT_NNP 1_CD mRNA_NN is_VBZ
        preferentially_RB expressed_VBN in_IN the_DT human_JJ enterocyte_NN compared_VBN
        to_TO ECaC_NNP 1_CD ,_, and_CC for_IN the_DT first_JJ time_NN demonstrate_VB that_IN
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN can_MD cause_VB a_DT rapid_JJ and_CC
        marked_VBD increase_NN in_IN CaT_NNP 1_CD mRNA_NN expression_NN in_IN the_DT enterocyte_NN ._.
        These_DT observations_NNS suggest_VBP a_DT likely_JJ important_JJ role_NN for_IN this_DT
        calcium_NN transporter_NN in_IN vitamin_NN D-_NNP dependent_JJ calcium_NN
        absorption_NN ._.
      
      
        Results_NNS and_CC Discussion_NNP
        
          CaT_NNP 1_CD is_VBZ expressed_VBN in_IN Caco-_NNP 2_CD cells_NNS
          We_PRP initially_RB addressed_VBD the_DT question_NN of_IN whether_IN Caco-_NNP 2_CD
          cells_NNS express_VBP ECaC_NNP 1_CD or_CC the_DT closely_RB related_VBN CaT_NNP 1_CD gene_NN ._.
          This_DT is_VBZ important_JJ because_IN it_PRP has_VBZ been_VBN suggested_VBN that_IN
          because_IN of_IN the_DT high_JJ degree_NN of_IN sequence_NN similarity_NN (_( 97_CD %_NN )_)
          between_IN the_DT CaT_NNP 1_CD and_CC ECaC_NNP 1_CD genes_NNS care_VBP should_MD be_VB taken_VBN in_IN
          interpreting_VBG data_NNS obtained_VBN by_IN hybridization_NN ,_, PCR_NNP or_CC other_JJ
          methodologies_NNS based_VBN on_IN nucleotide_NN sequences_NNS [_NN 24_CD ]_NN ._.
          First_CD ,_, the_DT PCR_NNP product_NN derived_VBN from_IN the_DT putative_JJ ECaC_NNP 1_CD or_CC
          CaT_NNP 1_CD gene_NN was_VBD purified_JJ and_CC sequenced_JJ ._. Based_VBN on_IN new_JJ
          sequence_NN information_NN (_( GenBank_NNP accession_NN number_NN AF_NNP 304464_CD
          (_( ECaC_NNP 1_LS )_) and_CC AF_NNP 365927_CD (_( CaT_NNP 1_LS )_) ,_, [_NN 25_CD ]_NN )_) the_DT nucleotides_NNS
          determined_VBD following_VBG the_DT sequencing_VBG of_IN our_PRP$ PCR_NNP product_NN
          from_IN Caco-_NNP 2_CD cells_NNS was_VBD an_DT identical_JJ match_NN for_IN CaT_NNP 1_CD rather_RB
          than_IN ECaC_NNP 1_CD (_( data_NNS not_RB shown_VBN )_) ._. Second_JJ ,_, the_DT sequences_NNS of_IN the_DT
          coding_VBG region_NN of_IN the_DT CaT_NNP 1_CD and_CC ECaC_NNP 1_CD genes_NNS (_( GenBank_NNP
          AF_NNP 365927_CD and_CC AF_NNP 304464_CD )_) indicate_VBP that_IN an_DT additional_JJ
          identification_NN step_NN based_VBN on_IN restriction_NN fragment_NN length_NN
          polymorphism_NN (_( RFLP_NNP )_) analysis_NN could_MD also_RB be_VB used_VBN to_TO
          confirm_VB the_DT identity_NN of_IN the_DT CaT_NNP 1_CD mRNA_NN in_IN Caco-_NNP 2_CD cells_NNS ._. As_IN
          described_VBD in_IN the_DT Method_NNP section_NN ,_, a_DT 259_CD bp_NN PCR_NNP product_NN was_VBD
          generated_VBN with_IN a_DT second_RB set_NN of_IN PCR_NNP primers_NNS that_WDT would_MD
          specifically_RB encompass_VB a_DT differential_JJ 
          Bgl_NNP 1_CD restriction_NN enzyme_NN cut_NN site_NN
          present_JJ in_IN CaT_NNP 1_CD but_CC not_RB ECaC_NNP 1_CD ._. Prior_RB to_TO electrophoresis_NNS
          on_IN a_DT 2_CD %_NN agarose_NN gel_NN ,_, the_DT amplified_VBN PCR_NNP product_NN was_VBD either_CC
          left_VBD untreated_JJ ,_, or_CC treated_VBD with_IN 
          Bgl_NNP 1_CD or_CC 
          BssHII_NNP restriction_NN enzymes_NNS ._. There_EX
          is_VBZ no_DT predicted_VBN 
          BssHII_NNP cut_VBD site_NN in_IN our_PRP$ amplified_VBN
          region_NN of_IN either_DT CaT_NNP 1_CD or_CC ECaC_NNP 1_CD based_VBN on_IN the_DT recently_RB
          published_VBN sequence_NN of_IN these_DT two_CD genes_NNS (_( GenBank_NNP AF_NNP 365927_CD
          and_CC AF_NNP 304464_CD )_) ._. Thus_RB ,_, 
          BssHII_NNP should_MD serve_VB as_IN negative_JJ
          control_NN for_IN the_DT restriction_NN enzyme_NN digestion_NN step_NN ._. In_IN
          contrast_NN ,_, the_DT location_NN of_IN the_DT single_JJ 
          BglI_NNP cut_VBD site_NN in_IN CaT_NNP 1_CD should_MD result_VB
          in_IN the_DT generation_NN of_IN two_CD smaller_JJR bands_NNS (_( ≅_NN 180_CD bp_NN and_CC ≅_NN 80_CD
          bp_NN )_) if_IN the_DT amplified_VBN PCR_NNP product_NN was_VBD CaT_NNP 1_CD ._. Since_IN ECaC_NNP 1_CD
          does_VBZ not_RB have_VB a_DT predicted_VBN 
          BglI_NNP site_NN in_IN the_DT amplified_VBN PCR_NNP
          product_NN ,_, no_DT smaller_JJR bands_NNS should_MD result_VB if_IN ECaC_NNP 1_CD was_VBD
          being_VBG amplified_VBN in_IN the_DT PCR_NNP reaction_NN ._. As_IN shown_VBN in_IN Figure_NN
          1_CD ,_, we_PRP found_VBD that_IN there_EX were_VBD two_CD smaller_JJR bands_NNS of_IN the_DT
          predicted_VBN size_NN and_CC no_DT larger_JJR 259_CD bp_NN band_NN remaining_VBG after_IN 
          Bgl_NNP 1_CD digestion_NN ,_, confirming_VBG the_DT
          identity_NN of_IN CaT_NNP 1_CD as_IN the_DT product_NN being_VBG amplified_VBN in_IN Caco-_NNP 2_CD
          cell_NN ._. In_IN addition_NN ,_, 
          BssHII_NNP restriction_NN enzyme_NN digestion_NN
          did_VBD not_RB result_VB in_IN smaller_JJR bands_NNS ,_, consistent_JJ with_IN a_DT likely_JJ
          specific_JJ action_NN of_IN 
          Bgl_NNP 1_CD digestion_NN of_IN CaT_NNP 1_CD under_IN the_DT
          digestion_NN conditions_NNS used_VBN ._. In_IN addition_NN ,_, further_JJ attempts_NNS
          at_IN PCR_NNP amplification_NN of_IN Caco-_NNP 2_CD cell_NN RNA_NNP with_IN other_JJ PCR_NNP
          primers_NNS designed_VBN to_TO specifically_RB amplify_VB ECaC_NNP 1_CD did_VBD not_RB
          result_VB in_IN an_DT amplified_VBN product_NN under_IN our_PRP$ conditions_NNS (_( data_NNS
          not_RB shown_VBN )_) ._. Thus_RB ,_, based_VBN on_IN this_DT collective_JJ information_NN ,_,
          we_PRP conclude_VBP that_IN CaT_NNP 1_CD ,_, but_CC not_RB ECaC_NNP 1_CD ,_, is_VBZ expressed_VBN in_IN
          Caco-_NNP 2_CD cells_NNS ._. It_PRP needs_VBZ to_TO be_VB pointed_VBN out_IN ,_, however_RB ,_, that_IN
          since_IN Caco-_NNP 2_CD cells_NNS are_VBP not_RB derived_VBN from_IN normal_JJ human_JJ
          intestinal_NN tissue_NN ,_, it_PRP is_VBZ possible_JJ that_IN ECaC_NNP 1_CD could_MD be_VB
          expressed_VBN in_IN the_DT human_JJ intestine_NN ._. However_RB ,_, our_PRP$
          observation_NN in_IN Caco-_NNP 2_CD cells_NNS is_VBZ consistent_JJ with_IN the_DT recent_JJ
          report_NN by_IN Barley_NNP and_CC colleagues_NNS [_NN 16_CD ]_NN indicating_VBG a_DT high_JJ
          expression_NN level_NN of_IN CaT_NNP 1_CD /_NN ECaC_NNP 2_CD in_IN human_JJ intestine_NN based_VBN
          on_IN Northern_NNP blotting_VBG ,_, and_CC similar_JJ findings_NNS by_IN Peng_NNP et_CC al_NN ._.
          [_NN 25_CD ]_NN using_VBG quantitative_JJ real-time_JJ PCR_NNP for_IN CaT_NNP 1_CD ,_, who_WP
          also_RB noted_VBD the_DT apparent_JJ absence_NN of_IN ECaC_NNP 1_CD /_NN CaT_NNP 2_CD in_IN human_JJ
          intestinal_NN tissue_NN ._.
        
        
          CaT_NNP 1_CD mRNA_NN is_VBZ regulated_VBN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN
          D_NNP
          Having_VBG established_VBD the_DT identity_NN of_IN CaT_NNP 1_CD in_IN Caco-_NNP 2_CD
          cells_NNS ,_, we_PRP then_RB studied_VBD the_DT effect_NN of_IN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN on_IN CaT_NNP 1_CD mRNA_NN
          expression_NN ._. If_IN CaT_NNP 1_CD is_VBZ an_DT important_JJ regulator_NN of_IN
          intestinal_NN calcium_NN absorption_NN ,_, it_PRP is_VBZ likely_JJ that_IN it_PRP would_MD
          be_VB regulated_VBN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ._. As_IN shown_VBN in_IN
          Figure_NN 2_CD ,_, treatment_NN of_IN cells_NNS for_IN 24_CD h_NN with_IN 10_CD -_: 7_CD mol_NN /_NN L_NNP
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP caused_VBD a_DT 10_CD -_: fold_VB increase_NN (_( p_NN <_NN
          0_CD ._. 001_CD ,_, ANOVA_NNP ,_, n_NN =_SYM 10_CD studies_NNS )_) in_IN CaT_NNP 1_CD mRNA_NN expression_NN ._. To_TO
          our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ demonstration_NN in_IN either_DT
          experimental_JJ animals_NNS or_CC human_JJ tissue_NN that_DT intestinal_NN CaT_NNP 1_CD
          expression_NN is_VBZ up_RB regulated_VBN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ._.
          This_DT finding_VBG may_MD provide_VB an_DT important_JJ molecular_JJ key_NN to_TO
          understand_VB the_DT mechanism_NN of_IN vitamin_NN D-_NNP mediated_JJ intestinal_NN
          calcium_NN absorption_NN ._. Moreover_RB ,_, given_VBN the_DT potentially_RB
          central_JJ role_NN of_IN this_DT epithelial_NN calcium_NN channel_NN as_IN an_DT
          important_JJ modulator_NN of_IN cellular_JJ calcium_NN influx_NN in_IN a_DT
          variety_NN of_IN cell_NN types_NNS [_NN 15_CD ]_NN ,_, it_PRP will_MD be_VB of_IN interest_NN to_TO
          investigate_VB whether_IN the_DT vitamin_NN D_NNP effect_NN on_IN CaT_NNP 1_CD
          expression_NN extends_VBZ beyond_IN the_DT enterocyte_NN ._. Vitamin_NNP D_NNP
          status_NN is_VBZ known_VBN to_TO influence_VB a_DT wide_JJ range_NN of_IN
          physiological_JJ systems_NNS including_VBG cells_NNS involved_VBN in_IN the_DT
          immune_JJ system_NN ,_, endocrine_NN function_NN ,_, prostate_NN ,_, skin_NN and_CC
          muscle_NN ._. Vitamin_NNP D_NNP effects_NNS on_IN CaT_NNP 1_CD expression_NN and_CC cellular_JJ
          calcium_NN influx_NN could_MD thereby_RB theoretically_RB modulate_VBP
          intracellular_NN calcium_NN and_CC cell_NN signaling_VBG in_IN a_DT variety_NN of_IN
          different_JJ tissues_NNS providing_VBG insight_NN into_IN understanding_VBG
          the_DT physiological_JJ effects_NNS of_IN vitamin_NN D_NNP throughout_IN the_DT
          body_NN ._. Peng_NNP and_CC colleagues_NNS [_NN 26_CD ]_NN have_VBP reported_VBN that_IN the_DT
          steroid_NN hormone_NN androgen_NN influences_VBZ CaT_NNP 1_CD mRNA_NN expression_NN
          in_IN LNCaP_NNP prostate_NN cells_NNS ._. We_PRP have_VBP not_RB yet_RB evaluated_VBN the_DT
          effects_NNS of_IN androgens_NNS on_IN CaT_NNP 1_CD expression_NN in_IN Caco-_NNP 2_CD cells_NNS ._.
          However_RB ,_, we_PRP have_VBP found_VBN (_( S_NNP ._. Taparia_NNP ,_, unpublished_JJ studies_NNS )_)
          that_IN all_DT steroid_NN hormones_NNS do_VBP not_RB share_VB this_DT effect_NN on_IN
          CaT_NNP 1_CD expression_NN because_IN 17_CD -_: β_NN estradiol_NN (_( 10_CD -_: 7_CD mol_NN /_NN L_NNP for_IN 24_CD
          h_NN )_) had_VBD no_DT effect_NN on_IN CaT_NNP 1_CD mRNA_NN expression_NN in_IN Caco-_NNP 2_CD cells_NNS ._.
          In_IN any_DT case_NN ,_, the_DT demonstrated_VBN effect_NN of_IN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP on_IN CaT_NNP 1_CD mRNA_NN shown_VBN here_RB in_IN Caco-_NNP 2_CD
          cells_NNS is_VBZ consistent_JJ with_IN the_DT idea_NN that_IN the_DT active_JJ
          metabolite_NN of_IN vitamin_NN D_NNP could_MD increase_VB the_DT number_NN of_IN CaT_NNP 1_CD
          calcium_NN transporters_NNS in_IN the_DT plasma_NN membrane_NN and_CC could_MD
          therefore_RB be_VB responsible_JJ for_IN the_DT higher_JJR rates_NNS of_IN calcium_NN
          influx_NN seen_VBN across_IN the_DT brush_NN border_NN membrane_NN in_IN vitamin_NN
          D-_NNP replete_JJ animals_NNS [_NN 9_CD 27_CD ]_NN thereby_RB playing_VBG a_DT key_JJ
          gatekeeper_NN role_NN in_IN increasing_VBG the_DT efficiency_NN of_IN
          intestinal_NN calcium_NN absorption_NN and_CC maintaining_VBG calcium_NN
          homeostasis_NNS ._.
        
        
          1_LS ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP causes_VBZ a_DT rapid_JJ and_CC marked_VBD
          up_RB regulation_NN of_IN CaT_NNP 1_CD expression_NN
          In_IN another_DT series_NN of_IN studies_NNS ,_, we_PRP addressed_VBD the_DT
          temporal_JJ and_CC dose-response_JJ effect_NN of_IN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP on_IN CaT_NNP 1_CD mRNA_NN expression_NN in_IN Caco-_NNP 2_CD
          cells_NNS ._. As_IN shown_VBN in_IN Figure_NN 3_CD ,_, the_DT response_NN of_IN CaT_NNP 1_CD mRNA_NN to_TO
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP is_VBZ rapid_JJ (_( n_NN =_SYM 6_CD studies_NNS )_) ._.
          Treatment_NNP with_IN 10_CD -_: 7_CD mol_NN /_NN L_NNP 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP
          increased_VBD (_( ~_NN 2_CD -_: fold_VB )_) CaT_NNP 1_CD mRNA_NN by_IN 2_CD h_NN ,_, the_DT earliest_JJS time_NN
          point_NN investigated_VBD ,_, and_CC clearly_RB elevated_VBD CaT_NNP 1_CD expression_NN
          by_IN 5_CD -_: fold_VB at_IN 4_CD h_NN ,_, with_IN progressively_RB higher_JJR expression_NN
          (_( up_IN to_TO 14_CD -_: fold_VB )_) at_IN the_DT later_JJ time_NN points_NNS ._.
          The_DT relationship_NN between_IN the_DT dose_NN of_IN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN and_CC CaT_NNP 1_CD mRNA_NN response_NN
          was_VBD investigated_VBN in_IN a_DT third_JJ set_VBN (_( n_NN =_SYM 3_CD studies_NNS )_) of_IN
          experiments_NNS at_IN 10_CD -_: 9_CD ,_, 10_CD -_: 8_CD ,_, and_CC 10_CD -_: 7_CD mol_NN /_NN L_NNP
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP for_IN 24_CD h_NN ._. In_IN these_DT studies_NNS there_RB
          was_VBD a_DT significant_JJ increase_NN in_IN CaT_NNP 1_CD mRNA_NN levels_NNS at_IN the_DT
          lowest_JJS dose_NN (_( 10_CD -_: 9_CD mol_NN /_NN L_NNP )_) of_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP
          studied_VBD (_( Figure_NN 4_LS )_) ,_, while_IN a_DT slightly_RB higher_JJR level_NN of_IN CaT_NNP 1_CD
          mRNA_NN expression_NN was_VBD observed_VBN at_IN 10_CD -_: 8_CD mol_NN /_NN L_NNP
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ,_, no_DT further_JJ effect_NN on_IN CaT_NNP 1_CD mRNA_NN
          was_VBD seen_VBN with_IN another_DT 10_CD -_: fold_VB increase_NN in_IN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP concentration_NN ._.
          The_DT rapid_JJ time_NN course_NN of_IN induction_NN and_CC sensitivity_NN of_IN
          CaT_NNP 1_CD mRNA_NN response_NN to_TO 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN
          supports_VBZ the_DT idea_NN that_IN CaT_NNP 1_CD could_MD play_VB a_DT role_NN as_IN a_DT
          gatekeeper_NN of_IN intestinal_NN calcium_NN absorption_NN ._. We_PRP have_VBP
          previously_RB reported_VBN that_IN it_PRP takes_VBZ from_IN 12_CD -_: 16_CD h_NN following_VBG
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN of_IN Caco-_NNP 2_CD cells_NNS to_TO
          first_JJ appreciate_VB an_DT increase_NN in_IN saturable_JJ transcellular_NN
          calcium_NN transport_NN [_NN 19_CD ]_NN ._. This_DT temporal_JJ response_NN is_VBZ
          similar_JJ to_TO the_DT 8_CD -_: 16_CD h_NN observed_VBD for_IN the_DT achievement_NN of_IN
          maximal_NN rates_NNS of_IN intestinal_NN calcium_NN absorption_NN in_IN vivo_NN
          following_VBG 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN of_IN vitamin_NN
          D-_NNP deficient_NN chickens_NNS [_NN 28_CD ]_NN ._. Future_NNP studies_NNS of_IN the_DT time_NN
          course_NN of_IN CaT_NNP 1_CD protein_NN expression_NN and_CC localization_NN of_IN
          this_DT protein_NN to_TO the_DT brush_NN border_NN will_MD be_VB necessary_JJ to_TO
          confirm_VB this_DT point_NN ,_, but_CC must_MD await_VB the_DT development_NN of_IN a_DT
          suitable_JJ CaT_NNP 1_CD antibody_NN ._.
        
        
          CaT_NNP 1_CD induction_NN precedes_VBZ the_DT increase_NN in_IN calbindin_NN D_NNP
          9_CD kmRNA_NN expression_NN
          It_PRP has_VBZ been_VBN argued_VBN [_NN 7_CD ]_NN that_IN the_DT cytosolic_JJ vitamin_NN
          D-_NNP dependent_JJ calcium_NN binding_JJ protein_NN calbindin_NN D_NNP 
          9_CD K_NNP is_VBZ the_DT likely_JJ rate-limiting_JJ step_NN in_IN
          vitamin_NN D-_NNP induced_VBD intestinal_NN calcium_NN absorption_NN ._. However_RB ,_,
          despite_IN a_DT considerable_JJ amount_NN of_IN associative_JJ evidence_NN [_NN 7_CD
          ]_NN ,_, there_EX has_VBZ long_RB been_VBN some_DT controversy_NN on_IN this_DT issue_NN [_NN
          29_CD 30_CD 31_CD ]_NN because_IN of_IN apparent_JJ discrepancies_NNS in_IN the_DT
          temporal_JJ pattern_NN of_IN calbindin_NN D_NNP 9_CD k_NN induction_NN compared_VBN to_TO
          calcium_NN absorption_NN following_VBG 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP
          treatment_NN in_IN experimental_JJ animals_NNS ._. Thus_RB ,_, in_IN the_DT current_JJ
          study_NN ,_, to_TO evaluate_VB a_DT possible_JJ gatekeeper_NN role_NN for_IN CaT_NNP 1_CD in_IN
          vitamin_NN D-_NNP mediated_JJ calcium_NN transport_NN we_PRP compared_VBD the_DT time_NN
          course_NN of_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP induction_NN of_IN calbindin_NN
          D_NNP 9_CD k_NN mRNA_NN and_CC CaT_NNP 1_CD mRNA_NN in_IN Caco-_NNP 2_CD cells_NNS ._. In_IN Caco-_NNP 2_CD cells_NNS ,_,
          the_DT mRNA_NN for_IN both_DT calbindin_NN D_NNP and_CC CaT_NNP 1_CD can_MD be_VB detected_VBN by_IN
          PCR_NNP in_IN the_DT absence_NN of_IN vitamin_NN D_NNP treatment_NN ._. The_DT
          concentration_NN of_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP in_IN the_DT basal_NN
          cell_NN culture_NN medium_NN is_VBZ approximately_RB 10_CD -_: 12_CD mol_NN /_NN L_NNP ._. As_IN
          illustrated_VBN in_IN Figure_NN 5_CD ,_, the_DT time_NN course_NN of_IN vitamin_NN
          D-_NNP dependent_JJ mRNA_NN induction_NN of_IN the_DT two_CD genes_NNS clearly_RB
          differs_VBZ with_IN CaT_NNP 1_CD expression_NN responding_VBG much_JJ earlier_RBR than_IN
          calbindin_NN D_NNP 9_CD k_NN ._. There_EX is_VBZ no_DT evident_JJ induction_NN of_IN calbindin_NN
          D_NNP mRNA_NN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP in_IN Caco-_NNP 2_CD cells_NNS up_IN to_TO 8_CD
          h_NN post_NN treatment_NN ._. In_IN these_DT experiments_NNS calbindin_NN D_NNP mRNA_NN
          was_VBD 3_CD -_: fold_VB greater_JJR than_IN control_NN by_IN 24_CD h_NN ._. In_IN contrast_NN ,_,
          CaT_NNP 1_CD mRNA_NN was_VBD clearly_RB increased_VBN (_( >_NN 5_CD -_: fold_VB )_) by_IN 4_CD h_NN post_NN
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN in_IN the_DT same_JJ cells_NNS ._.
          These_DT observations_NNS will_MD need_VB to_TO be_VB expanded_VBN in_IN the_DT future_NN
          to_TO include_VB measurement_NN of_IN the_DT relevant_JJ proteins_NNS ._. However_RB ,_,
          such_JJ association_NN studies_NNS will_MD not_RB completely_RB settle_VB the_DT
          question_NN of_IN the_DT relative_JJ importance_NN of_IN either_DT of_IN these_DT
          vitamin_NN D-_NNP induced_VBD genes_NNS in_IN the_DT calcium_NN transport_NN response_NN
          to_TO 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP ._. Those_DT questions_NNS will_MD be_VB
          likely_RB answered_VBN more_RBR directly_RB in_IN the_DT future_NN by_IN
          individually_RB altering_VBG the_DT expression_NN of_IN these_DT calcium_NN
          transport_NN genes_NNS in_IN transfected_JJ cell_NN lines_NNS or_CC in_IN
          transgenic_JJ animal_NN models_NNS ._.
          Given_VBN what_WP is_VBZ already_RB known_VBN about_IN the_DT characteristics_NNS
          of_IN the_DT epithelial_NN calcium_NN channels_NNS and_CC calbindin_NN D_NNP ,_, it_PRP is_VBZ
          a_DT plausible_JJ hypothesis_NNS that_IN CaT_NNP 1_CD and_CC calbindin_NN D_NNP could_MD
          work_VB in_IN tandem_JJ to_TO maintain_VB high_JJ rates_NNS of_IN calcium_NN
          absorption_NN ._. Studies_NNS in_IN human_JJ duodenal_JJ biopsy_NN specimens_NNS
          have_VBP found_VBN a_DT significant_JJ correlation_NN between_IN CaT_NNP 1_CD mRNA_NN
          and_CC calbindin_NN D_NNP mRNA_NN expression_NN [_NN 16_CD ]_NN ._. Thus_RB ,_, as_IN a_DT
          working_VBG hypothesis_NNS ,_, we_PRP propose_VBP that_IN during_IN times_NNS of_IN
          dietary_JJ calcium_NN stress_NN ,_, or_CC during_IN periods_NNS of_IN high_JJ calcium_NN
          demand_NN ,_, CaT_NNP 1_CD expression_NN in_IN the_DT enterocyte_NN is_VBZ increased_VBN by_IN
          a_DT vitamin_NN D-_NNP dependent_JJ mechanism_NN ._. This_DT regulatory_JJ genomic_JJ
          response_NN of_IN the_DT enterocyte_NN would_MD result_VB in_IN an_DT increase_NN in_IN
          the_DT brush_NN border_NN membrane_NN content_NN of_IN CaT_NNP 1_CD calcium_NN influx_NN
          channels_NNS that_WDT could_MD function_VB as_IN a_DT gatekeeper_NN mechanism_NN to_TO
          augment_VB the_DT rate_NN of_IN calcium_NN entry_NN across_IN the_DT apical_JJ
          membrane_NN [_NN 9_CD ]_NN ._. However_RB ,_, given_VBN that_IN there_EX is_VBZ a_DT
          Ca-dependent_NNP negative_JJ feedback_NN mechanism_NN to_TO limit_VB calcium_NN
          entry_NN through_IN the_DT channel_NN by_IN maintaining_VBG the_DT channel_NN in_IN
          the_DT closed_VBN position_NN [_NN 14_CD 15_CD ]_NN there_EX must_MD be_VB a_DT way_NN to_TO
          remove_VB calcium_NN from_IN the_DT vicinity_NN of_IN the_DT cytosolic_JJ face_NN of_IN
          the_DT channel_NN to_TO optimize_NN and_CC sustain_VB calcium_NN influx_NN rates_NNS ._.
          The_DT coordinated_VBN vitamin_NN D-_NNP dependent_JJ induction_NN of_IN the_DT
          cytosolic_JJ calcium-binding_JJ protein_NN calbindin_NN D_NNP could_MD serve_VB
          this_DT function_NN when_WRB the_DT need_NN for_IN transcellular_NN calcium_NN
          flux_NN is_VBZ high_JJ by_IN acting_VBG directly_RB or_CC indirectly_RB as_IN a_DT
          molecular_JJ sponge_NN and_CC selectively_RB removing_VBG calcium_NN ions_NNS
          from_IN the_DT CaT_NNP 1_CD channel_NN and_CC /_NN or_CC to_TO buffer_VB increases_NNS in_IN
          intracellular_NN calcium_NN ,_, thereby_RB preventing_VBG premature_JJ
          inactivation_NN of_IN this_DT I_PRP 
          CRAC_NNP channel_NN [_NN 15_CD ]_NN ._. Calbindin_NNP D_NNP
          could_MD also_RB play_VB its_PRP$ traditionally_RB conceived_VBD role_NN as_IN a_DT
          calcium_NN chaperone_NN protein_NN to_TO facilitate_VB the_DT transfer_NN of_IN
          calcium_NN through_IN the_DT cytosol_NN [_NN 32_CD ]_NN and_CC perhaps_RB delivery_NN
          of_IN Ca_MD +_NN +_NN to_TO the_DT basolateral_NN ATP-dependent_NNP calcium_NN pump_NN for_IN
          extrusion_NN out_IN of_IN the_DT enterocyte_NN [_NN 33_CD ]_NN ._.
        
      
      
        Conclusions_NNP
        These_DT observations_NNS are_VBP the_DT first_JJ to_TO demonstrate_VB
        regulation_NN of_IN CaT_NNP 1_CD expression_NN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP in_IN
        the_DT human_JJ enterocyte_NN and_CC are_VBP consistent_JJ with_IN a_DT new_JJ model_NN of_IN
        intestinal_NN calcium_NN absorption_NN wherein_WRB vitamin_NN D-_NNP mediated_JJ
        changes_NNS in_IN brush_NN border_NN membrane_NN CaT_NNP 1_CD levels_NNS could_MD be_VB the_DT
        primary_JJ gatekeeper_NN regulating_VBG homeostatic_JJ modulation_NN of_IN
        intestinal_NN calcium_NN absorption_NN efficiency_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Conditions_NNP of_IN cell_NN culture_NN
          Caco-_NNP 2_CD cells_NNS (_( HTB_NNP 37_CD ,_, ATCC_NNP ,_, Rockville_NNP ,_, MD_NNP )_) were_VBD
          propagated_JJ and_CC maintained_VBN as_IN described_VBN previously_RB [_NN 17_CD ]_NN
          ._. Caco-_NNP 2_CD cells_NNS were_VBD studied_VBN between_IN passages_NNS 30_CD -_: 40_CD ._. Cells_NNP
          were_VBD seeded_VBN into_IN six-well_JJ dishes_NNS (_( 35_CD -_: mm_NN diameter_NN ;_: Costar_NNP ,_,
          Cambridge_NNP ,_, MA_NNP )_) and_CC grown_VBN for_IN 15_CD days_NNS ._. Cell_NNP culture_NN
          medium_NN ,_, nutrients_NNS and_CC antibiotics_NNS were_VBD purchased_VBN from_IN
          BioWhittaker_NNP (_( Walkersville_NNP ,_, MD_NNP )_) ._. FBS_NNP was_VBD purchased_VBN from_IN
          HyClone_NNP Laboratories_NNPS (_( Logan_NNP ,_, Utah_NNP )_) ._. Chemicals_NNS were_VBD
          purchased_VBN from_IN Sigma_NNP Chemical_NNP Co_NNP ._. (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) and_CC
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP was_VBD purchased_VBN from_IN Biomol_NNP
          Research_NNP Laboratories_NNPS (_( Plymouth_NNP Meeting_VBG ,_, PA_NNP )_) ._.
        
        
          Cell_NNP treatments_NNS
          In_IN time-course_JJ studies_NNS ,_, cells_NNS were_VBD treated_VBN with_IN 100_CD
          nanomol_NN /_NN L_NNP 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP diluted_VBD in_IN DMEM_NNP +_NN 5_CD %_NN
          FBS_NNP for_IN 0_CD ,_, 2_CD h_NN ,_, 4_CD h_NN ,_, 8_CD h_NN and_CC 24_CD h_NN ._. All_DT treatments_NNS ended_VBD
          at_IN the_DT 24_CD h_NN time_NN point_NN ._. Control_NN treatments_NNS were_VBD treated_VBN
          with_IN ethanol_NN vehicle_NN alone_RB ._. In_IN dose-response_JJ studies_NNS ,_,
          cells_NNS were_VBD treated_VBN for_IN 24_CD h_NN with_IN 0_CD ,_, 1_CD ,_, 10_CD ,_, or_CC 100_CD nanomol_NN /_NN L_NNP
          1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP diluted_VBD in_IN DMEM_NNP +_NN 5_CD %_NN FBS_NNP ._. Control_NN
          cells_NNS were_VBD treated_VBN with_IN ethanol_NN vehicle_NN ._.
        
        
          Reverse_VBP transcription_NN polymerase_NN chain_NN reaction_NN
          (_( RT-PCR_NNP )_)
          Following_VBG experimental_JJ treatments_NNS ,_, cells_NNS were_VBD
          harvested_VBN and_CC total_JJ RNA_NNP was_VBD isolated_VBN according_VBG to_TO
          manufacturer_NN 's_POS instructions_NNS (_( Tri_NNP Reagent_NNP ,_, Molecular_NNP
          Research_NNP Center_NNP ,_, Cincinnati_NNP ,_, OH_NNP )_) ._. One_CD microgram_NN of_IN total_JJ
          RNA_NNP was_VBD made_VBN into_IN a_DT cDNA_NN library_NN by_IN a_DT reverse_JJ
          transcription_NN process_NN using_VBG the_DT following_JJ conditions_NNS :_: 0_CD ._. 1_CD
          ug_NN of_IN oligothymidine_NN ,_, 100_CD U_NNP of_IN reverse_NN transcriptase_NN ,_, 5_CD
          ug_NN bovine_JJ serum_NN albumin_NN (_( BSA_NNP )_) ,_, 10_CD U_NNP RNAsin_NNP (_( Promega_NNP ,_,
          Madison_NNP WI_NNP )_) in_IN a_DT final_JJ volume_NN of_IN 10_CD ul_NN buffer_NN containing_VBG
          50_CD mM_NN Tris-_NNP HCl_NNP (_( pH_NN 8_CD ._. 3_LS )_) ,_, 75_CD mM_NN KCl_NNP ,_, 3_CD mM_NN MgCl_NNP 
          2_CD ,_, 10_CD mM_NN dithiothreitol_NN ,_, 0_CD ._. 5_CD mM_NN each_DT
          of_IN CTP_NNP ,_, ATP_NNP ,_, GTP_NNP ,_, TTP_NNP ,_, incubated_JJ for_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP ,_, and_CC
          denatured_JJ at_IN 95_CD °_NN C_NNP for_IN 10_CD minutes_NNS ._. The_DT cDNA_NN solution_NN
          containing_VBG 0_CD ._. 1_CD μg_NN equivalent_NN RNA_NNP was_VBD analyzed_VBN by_IN PCR_NNP for_IN
          GAPDH_NNP ,_, human_JJ calbindin_NN D_NNP 
          9_CD K_NNP ,_, and_CC human_JJ CaT_NNP /_NN ECaC_NNP ._. Primers_NNP sets_NNS
          for_IN the_DT epithelial_NN calcium_NN channel_NN were_VBD as_IN follows_VBZ :_: sense_NN
          primer_NN 5_CD '_POS TGAACCTGGTGCGCGCACTGC_NNP 3_CD '_POS (_( GenBank_NNP accession_NN
          number_NN AJ_NNP 271207_CD ._. 1_LS nucleotides_NNS 480_CD -_: 500_CD )_) and_CC antisense_NN
          primer_NN 5_CD '_POS CCCAGGGAGTCCTGGGCCCGGA_NNP 3_CD '_POS (_( nucleotides_NNS 657_CD -_: 678_CD )_) ._.
          The_DT PCR_NNP primers_NNS used_VBN for_IN GAPDH_NNP and_CC calbindin_NN D_NNP were_VBD as_RB
          previously_RB described_VBD [_NN 22_CD ]_NN ._. PCR_NNP conditions_NNS used_VBN were_VBD :_:
          denature_NN at_IN 94_CD °_NN C_NNP for_IN 40_CD s_VBZ ,_, annealing_VBG at_IN 55_CD °_NN C_NNP for_IN 50_CD s_VBZ
          with_IN an_DT extension_NN at_IN 72_CD °_NN C_NNP for_IN 50_CD s_VBZ ._. All_DT reactions_NNS were_VBD
          run_VBN within_IN the_DT linear_JJ range_NN of_IN number_NN of_IN cycles_NNS to_TO
          product_NN formed_VBN ._. GAPDH_NNP was_VBD amplified_VBN for_IN 21_CD cycles_NNS ,_, CaT_NNP 1_CD
          for_IN 28_CD cycles_NNS and_CC calbindin_NN D_NNP 
          9_CD K_NNP for_IN 28_CD cycles_NNS ._. A_DT blank_JJ PCR_NNP was_VBD run_VBN
          using_VBG water_NN for_IN each_DT gene_NN tested_VBN ._. PCR_NNP products_NNS were_VBD
          electrophoresed_JJ on_IN a_DT 2_CD %_NN agarose_NN gel_NN containing_VBG ethidium_NN
          bromide_NN ._. Relative_NNP amounts_NNS of_IN amplified_VBN PCR_NNP product_NN from_IN
          each_DT experimental_JJ condition_NN were_VBD visualized_JJ under_IN
          ultraviolet_NN light_JJ and_CC digitized_JJ with_IN the_DT Gel_NNP Doc_NNP 2000_CD gel_NN
          documentation_NN system_NN (_( Bio-_NNP Rad_NNP Laboratories_NNPS ,_, Hercules_NNP ,_,
          CA_NNP )_) ._. Relative_NNP amounts_NNS of_IN product_NN were_VBD estimated_VBN by_IN
          digital_JJ densitometry_NN using_VBG Quantity_NNP One_CD (_( version_NN 4_LS )_)
          quantitation_NN software_NN (_( Bio-_NNP Rad_NNP )_) ._. CaT_NNP 1_CD and_CC calbindin_NN D_NNP 
          9_CD K_NNP mRNA_NN expression_NN were_VBD normalized_JJ
          relative_NN to_TO the_DT expression_NN of_IN GAPDH_NNP mRNA_NN ,_, a_DT
          constitutively_RB expressed_VBN gene_NN whose_WP$ levels_NNS were_VBD not_RB
          affected_VBN by_IN 1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP treatment_NN ._.
        
        
          Sequencing_NNP and_CC RFLP_NNP analysis_NN to_TO establish_VB the_DT
          identity_NN of_IN CaT_NNP 1_CD in_IN Caco-_NNP 2_CD Cells_NNP
          PCR_NNP products_NNS from_IN the_DT epithelial_NN calcium_NN channel_NN were_VBD
          generated_VBN with_IN the_DT primers_NNS described_VBD above_IN ,_, subjected_VBN to_TO
          electrophoresis_NNS on_IN a_DT 1_CD %_NN low-melting-point_JJ agarose_NN gel_NN ,_,
          and_CC purified_JJ for_IN sequence_NN verification_NN ._. The_DT DNA_NNP
          sequencing_VBG facility_NN at_IN Tufts_NNP University_NNP sequenced_JJ the_DT PCR_NNP
          product_NN to_TO identify_VB whether_IN the_DT amplified_VBN PCR_NNP product_NN
          from_IN Caco-_NNP 2_CD cells_NNS was_VBD either_CC CaT_NNP 1_CD or_CC the_DT closely_RB related_VBN
          ECaC_NNP 1_CD sequence_NN ._. Because_IN of_IN the_DT high_JJ nucleotide_NN similarity_NN
          of_IN CaT_NNP 1_CD and_CC ECaC_NNP 1_CD (_( 97_CD %_NN )_) ,_, an_DT additional_JJ identification_NN
          step_NN based_VBN on_IN restriction_NN fragment_NN length_NN polymorphism_NN
          (_( RFLP_NNP )_) analysis_NN was_VBD also_RB conducted_VBN to_TO confirm_VB the_DT
          identity_NN of_IN CaT_NNP 1_CD in_IN Caco-_NNP 2_CD cells_NNS ._. PCR_NNP products_NNS were_VBD
          generated_VBN using_VBG the_DT following_NN primer_NN set_VBN :_: sense_NN primer_NN
          (_( 5_CD '_POS TGACATCTGAGCTCTATGAGGGT_NNP 3_CD '_POS ,_, GenBank_NNP AF_NNP 365927_CD
          nucleotides_NNS 545_CD -_: 567_CD )_) and_CC antisense_NN primer_NN
          5_CD '_POS CCCAGGGAGTCCTGGGCCCGGA_NNP 3_CD '_POS (_( nucleotides_NNS 782_CD -_: 803_CD )_) ._. These_DT
          primers_NNS yield_VBP a_DT 259_CD bp_NN PCR_NNP product_NN with_IN a_DT specific_JJ
          restriction_NN site_NN that_WDT makes_VBZ it_PRP possible_JJ to_TO clearly_RB
          distinguish_VB between_IN CaT_NNP 1_CD and_CC ECaC_NNP 1_CD using_VBG the_DT restriction_NN
          enzymes_NNS 
          Bgl_NNP 1_CD (_( New_NNP England_NNP Biolabs_NNP )_) ._. In_IN this_DT
          PCR_NNP amplified_VBN product_NN ,_, there_EX is_VBZ no_DT predicted_VBN 
          Bgl_NNP 1_CD restriction_NN enzyme_NN site_NN in_IN the_DT
          corresponding_JJ ECaC_NNP 1_CD sequence_NN ._. In_IN contrast_NN ,_, the_DT presence_NN
          of_IN this_DT 
          Bgl_NNP 1_CD cut_VB site_NN in_IN the_DT CaT_NNP 1_CD sequence_NN
          will_MD result_VB in_IN two_CD smaller_JJR bands_NNS (_( ≅_NN 180_CD and_CC ≅_NN 80_CD bp_NN )_)
          after_IN digestion_NN with_IN the_DT endonuclease_NN ._. The_DT endonuclease_NN
          digested_VBN and_CC undigested_JJ PCR_NNP samples_NNS were_VBD electrophoresed_JJ
          on_IN a_DT 2_CD %_NN agarose_NN gel_NN and_CC the_DT bands_NNS were_VBD visualized_JJ with_IN
          ethidium_NN bromide_NN staining_VBG ._. The_DT size_NN of_IN the_DT cut_NN bands_NNS was_VBD
          estimated_VBN with_IN standard_JJ 50_CD pb_NN markers_NNS to_TO identify_VB whether_IN
          the_DT PCR_NNP product_NN amplified_VBN from_IN Caco-_NNP 2_CD cells_NNS was_VBD being_VBG cut_NN
          into_IN the_DT appropriately_RB sized_VBD bands_NNS with_IN 
          Bgl_NNP 1_CD ._.
        
        
          Data_NNP analysis_NN
          Data_NNP are_VBP reported_VBN as_IN mean_NN ±_NN the_DT standard_JJ error_NN of_IN the_DT
          mean_NN (_( SEM_NNP )_) ._. Experiments_NNS were_VBD repeated_VBN from_IN 3_CD to_TO 10_CD times_NNS ._.
          Treatment_NNP effects_NNS were_VBD evaluated_VBN by_IN ANOVA_NNP with_IN a_DT post_NN hoc_FW
          Tukey_NNP test_NN for_IN individual_JJ treatment_NN comparisons_NNS (_( SYSTAT_NNP
          version_NN 9_CD ,_, SAS_NNP Institute_NNP ,_, Cary_NNP NC_NNP )_) where_WRB applicable_JJ ._.
        
      
    
  
